What is the recommended antibiotic regimen for post‑exposure prophylaxis after a gonorrhea exposure?

Post-Exposure Prophylaxis for Gonorrhea: Not Routinely Recommended

Automatic antibiotics after gonorrhea exposure are not standard practice—the evidence provided addresses treatment of confirmed infection and doxycycline post-exposure prophylaxis (doxyPEP) for broader STI prevention, not specific gonorrhea post-exposure prophylaxis.

Understanding the Clinical Context

The question asks about post-exposure prophylaxis specifically for gonorrhea, but the available guidelines focus on two distinct scenarios:

Treatment of Confirmed Gonorrhea Infection

When gonorrhea is diagnosed (not just exposure), CDC recommends combination therapy with ceftriaxone 250 mg intramuscularly PLUS azithromycin 1 g orally as a single dose 1. This applies to urogenital, anorectal, and pharyngeal infections. Azithromycin is preferred over doxycycline due to single-dose convenience and lower tetracycline resistance rates 1.

DoxyPEP for Bacterial STI Prevention

The 2024 CDC guidelines address doxycycline post-exposure prophylaxis (doxyPEP) for men who have sex with men (MSM) and transgender women at substantial risk for bacterial STIs 2. This involves taking doxycycline 200 mg within 72 hours after condomless sex to prevent chlamydia, syphilis, and gonorrhea.

Key Distinction: Exposure vs. Prevention Strategy

There is no established "automatic antibiotic" regimen specifically for known gonorrhea exposure in the traditional sense of post-exposure prophylaxis. The evidence shows:

• Historical data from 1979 demonstrated that minocycline prophylaxis after sexual exposure had limited effectiveness and selected for resistant gonococci 3
• Current practice focuses on testing exposed partners and treating confirmed infections, not presumptive treatment of all exposures

Partner Management Approach

When someone is diagnosed with gonorrhea, their sexual partners from the preceding 60 days should be:

1. Evaluated and tested for gonorrhea and chlamydia
2. Treated with the recommended regimen (ceftriaxone 250 mg IM + azithromycin 1 g PO) 1
3. Given expedited partner therapy if they cannot be linked to timely evaluation—this involves providing oral combination therapy (cefixime 400 mg + azithromycin 1 g) to the partner through the patient or pharmacy 1

DoxyPEP Considerations for Gonorrhea

While doxyPEP shows promise for STI prevention in high-risk populations, its effectiveness against gonorrhea is limited and declining:

• Population-level data from San Francisco showed doxyPEP was associated with decreased chlamydia (-49.64%) and syphilis (-51.39%), but increased gonorrhea cases (+1.77% per month) 4
• Tetracycline resistance in N. gonorrhoeae is high globally (median 54.2%, ranging 4-100%), with highest rates in East Asia/Pacific (82.1%) and sub-Saharan Africa (81.6%) 5
• Modeling studies predict doxyPEP accelerates tetracycline resistance, with clinical effectiveness potentially lost within 1.6-12.1 years depending on uptake 6

Clinical Pitfalls to Avoid

1. Do not confuse doxyPEP with gonorrhea post-exposure prophylaxis—doxyPEP is a broader prevention strategy for high-risk populations, not a response to known gonorrhea exposure
2. Do not use doxycycline alone to treat gonorrhea—it is ineffective due to widespread resistance
3. Do not delay testing exposed partners—presumptive treatment without testing misses the opportunity for antimicrobial susceptibility monitoring
4. Do not assume doxyPEP prevents gonorrhea effectively—resistance patterns make this increasingly unreliable

Practical Recommendation

For a patient with known gonorrhea exposure:

• Test for gonorrhea (and chlamydia) at exposed anatomic sites
• If testing is immediately available and follow-up assured: await results before treating
• If testing/follow-up is uncertain: provide expedited partner therapy with ceftriaxone 250 mg IM + azithromycin 1 g PO (or oral alternative: cefixime 400 mg + azithromycin 1 g with test-of-cure in 1 week) 1

For MSM/transgender women at substantial ongoing STI risk: Consider doxyPEP (200 mg within 72 hours after sex, maximum 200 mg per 24 hours) as part of comprehensive prevention, recognizing limited and declining effectiveness against gonorrhea 2.